Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report Letter

publication date

  • June 24, 2022

webpage

published in

keywords

  • bullous drug eruption
  • bullous pemphigoid
  • dupilumab
  • immune-related adverse events
  • immunotherapy
  • pembrolizumab